Immunomedics Reports Responses with Sacituzumab Govitecan (immu-132) in Patients with Metastatic Solid Cancers Who Failed Prior Checkpoint-inhibitor Therapy

Boston, MA, April 29, 2016 --Immunomedics, Inc. (Nasdaq: IMMU) today announced that objective durable responses have been achieved with sacituzumab govitecan, its lead antibodydrug conjugate (ADC), in a number of patients with advanced, metastatic solid cancers, after failing multiple prior therapies, some including checkpoint inhibitors (CPIs). The ADC has previously been granted Breakthrough Therapy Designation from the FDA for the treatment of patients with triple-negative breast cancer (TNBC) who have failed prior therapies for metastatic disease.